Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNAP: CT1812 in mild to moderate Alzheimer's disease
NCT03522129Phase 1Completed
- Sponsor
- Cognition Therapeutics, Inc.
- Start
- May 2018
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pirfenidone in Alzheimer's disease (AD) (4 arms), sponsored by Cognition Therapeutics, Inc. Primary endpoint: Change from baseline CSF Amyloid beta oligomer concentration at 48 hours. Started May 2018; status: completed.
02
Drugs
pirfenidone
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03522129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03522129.